Synthetic melanotropin (α-melanocyte-stimulating hormone, α-MSH) is a 13-amino acid acetylated and amidated peptide with the sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, C₇₇H₁₀₉N₂₁O₁₉S, molar mass 1664.9 g/mol. Solid-phase peptide synthesis under Fmoc/tBu chemistry typically uses Rink amide MBHA resin at a substitution capacity of 0.25–0.45 mmol/g, with each amino acid coupling carried out at 2–4 equiv relative to free amino-terminal resin sites. Activation with HBTU/HOBt in DMF proceeds at 25 ± 3 °C for 20–45 min per cycle, and deletion sequences are monitored by ninhydrin or chloranil testing before the next coupling step. GMP synthesis is conducted under the framework of ICH Q7 for active pharmaceutical ingredients, with analytical release under USP <71> for sterility and Ph. Eur. 2.2.46 for chromatographic separation; ICH Q3D is applied to elemental impurity risk assessment in the final lyophilizate. Cleavage from the resin uses trifluoroacetic acid/triisopropylsilane/water at a volumetric ratio of 95:2.5:2.5 for 2–3 h at 25 ± 2 °C. The crude peptide is precipitated in cold methyl tert-butyl ether at −20 °C, then loaded onto a preparative C18 column of 250 × 20 mm packed with 10 µm silica, eluted at 15 mL/min with mobile phase A consisting of 0.1% trifluoroacetic acid in water and mobile phase B consisting of 0.1% trifluoroacetic acid in acetonitrile using a linear gradient from 10% to 40% B over 40 min. The main product fraction is lyophilized at a shelf temperature of −40 °C and condenser temperature of −80 °C; oxidation of the methionine residue is limited by nitrogen overlay and exclusion of metal-contact surfaces in the preparative flow path. Preparative HPLC pooling must exclude the trailing edge of the main peak because methionine sulfoxide impurities accumulate in that fraction and alter subsequent peptide acetate assay values. Terminal product types from this route include lyophilized α-MSH acetate, research-grade peptide powders, process intermediates for melanocortin receptor agonist development, and HPLC reference materials. Residual trifluoroacetate must be removed by lyophilization and confirmed by ion chromatography because incomplete removal creates a hygroscopic salt form and shifts the net peptide content.

When α-MSH is used as a plasma immunoassay calibrator, what reconstitution and dilution limits prevent peptide loss to container surfaces?

After reconstitution of the lyophilized peptide, adsorption to uncoated borosilicate glass can be reduced by using siliconized polypropylene tubes and by adding 0.1% w/v human serum albumin or 0.1% w/v casein to the diluent. A calibrator panel in charcoal-stripped human plasma is prepared at 0 pg/mL, 50 pg/mL, 150 pg/mL, 500 pg/mL, and 1500 pg/mL, with the 0 pg/mL level prepared from the same matrix to control for endogenous α-MSH background. Stock solution is prepared at 1.0 mg/mL in 10 mmol/L phosphate-buffered saline, pH 7.4, then serially diluted with a step dilution factor not exceeding 1:100 to reduce aggregation and surface denaturation. The downstream process includes adding aprotinin at 0.6 TIU/mL and EDTA at 1 mg/mL to plasma before formulation, lyophilization in 2 mL amber vials under nitrogen backfill, and storage at −20 °C with moisture-indicating stoppers. Production-scale kit filling uses automated liquid handling with disposable low-retention tips and intermediate precision checks aligned with CLSI EP06-A linearity evaluation. Quality management for these calibration materials follows ISO 13485:2016, and method validation is aligned with ICH Q2(R2), with accuracy and precision acceptance criteria set at ±15% relative error for calibrators and ±20% at the lower limit of quantification. Terminal product types include quantitative α-MSH ELISA calibrator sets, radioimmunoassay controls, and external quality assessment panels supplied to clinical laboratory proficiency testing schemes. Container type must be verified during method transfer because unsiliconized glass and repeated freeze-thaw cycles produce nonlinear recovery at the low calibrator level.

Melanocortin receptor radioligand synthesis and kit-scale ⁶⁸Ga chelation parameters

Upon conjugation of a DOTA chelator to the N-terminus of the protected or unprotected 13-amino acid peptide, the resulting precursor is lyophilized into sterile kit vials at 10–50 µg peptide conjugate per vial. A typical radiolabeling kit formulation contains 10–50 µg peptide-DOTA conjugate, 20–30 mg sodium acetate trihydrate as buffer, and 5–10 mg ascorbic acid as radioprotectant; reconstitution is performed with 370–740 MBq of freshly eluted ⁶⁸GaCl₃ in 0.1 M hydrochloric acid, adjusted to pH 3.5–4.0 with 0.25 M sodium acetate, followed by heating at 95 °C for 10 min. The crude radiolabeled peptide is purified by reverse-phase C18 solid-phase extraction using ethanol/water elution, then aseptically formulated in 0.9% w/v sodium chloride for injection. Compliance for investigational use is anchored to USP 823 for positron emission tomography drug production, Ph. Eur. radiopharmaceutical preparations monograph 0125, and ICH Q3C for residual solvent control in the final injectable solution. Terminal product types include investigational PET imaging kits for melanocortin-1 receptor positive melanoma lesions, lyophilized peptide-chelate precursor vials, and cold kit radiochemical purity test standards. A production limitation is that pH below 3.5 slows chelation kinetics and increases free ⁶⁸Ga colloid formation, whereas pH above 4.0 can precipitate the peptide; published data for full-scale GMP validation of this specific melanoma tracer configuration is limited, so kit-scale stability requires site-specific pre-validation.

Because the stratum corneum is the primary barrier to peptide diffusion, static Franz diffusion cells with a receptor volume of 6–8 mL and a diffusional surface area of 1.77 cm² are used to evaluate synthetic α-MSH permeation through heat-separated human epidermis mounted with the stratum corneum facing the donor compartment. The donor formulation is prepared with 0.01–0.05 wt% α-MSH in 10 mmol/L phosphate-buffered saline, pH 7.4, and thickened with 0.5% w/v hydroxyethylcellulose to provide sufficient residence time on the skin surface; the receptor medium consists of 0.01 M phosphate-buffered saline with 0.05% w/v sodium azide maintained at 32 ± 0.5 °C and stirred at 400 rpm. Samples are withdrawn at 0.5, 1, 2, 4, 6, 8, and 24 h with replacement of equal receptor volume, and the peptide is quantified by LC-MS/MS with a lower limit of quantification below 0.1 ng/mL. Industry compliance is defined by OECD TG 428 for in vitro skin absorption and ISO 10993-23:2021 for in vitro irritation testing when the donor formulation is subsequently assessed for medical device components; ICH Q3C(R8) applies to residual solvent limits if co-solvents such as ethanol or propylene glycol are introduced to enhance penetration. Terminal product types include transdermal peptide delivery feasibility formulations, ex vivo permeation test articles for preclinical pharmacokinetic screening, and dermatological drug delivery candidates intended for further clinical evaluation. A major operational boundary is the stratum corneum’s proteolytic and barrier activity against the 1664.9 g/mol peptide; without microneedle pretreatment, chemical enhancers, or encapsulation, observed permeation is low and published data for this specific configuration is limited.

Cell culture supplementation in serum-free melanocyte differentiation media requires stepwise acclimation to avoid melanin cytotoxicity

When primary melanocytes are transferred from expansion medium to differentiation conditions, synthetic α-MSH is supplemented at a working concentration of 10–100 nmol/L, prepared from a sterile-filtered stock solution of 100 µmol/L in 10 mmol/L phosphate-buffered saline, pH 7.4. The working medium is replaced every 48 h, and cells are seeded at 5 × 10³–1 × 10⁴ cells/cm² in vessels coated with bovine plasma fibronectin at 1–5 µg/cm². The downstream process includes thawing cryopreserved melanocytes in melanocyte growth medium, expansion without α-MSH for 48–72 h, then switching to α-MSH-supplemented differentiation medium for 7–14 days under 37 °C, 5% CO₂, 95% relative humidity. Industry standards include ISO 9001:2015 for cell culture media manufacturing, USP <71> sterility testing of the peptide stock, and ISO 10993-5:2009 for cytotoxicity assessment when the resulting melanocyte-containing construct is used as part of a medical device biological evaluation. Terminal product types include primary human melanocyte cultures, reconstructed human epidermis used for pigmentation and phototoxicity testing, and melanin quantification assay kits. The operational boundary is that continuous α-MSH exposure beyond 14 days leads to intracellular melanin concentrations that can interfere with tetrazolium-based viability assays, and repeated freeze-thaw of the stock solution reduces melanogenic activity; single-use aliquots are therefore stored at −80 °C.

If a lyophilized α-MSH lot is assigned as an HPLC system suitability standard, orthogonal purity assignment by amino acid analysis is required

A lyophilized α-MSH reference standard is not a primary standard unless purity is assigned by mass balance and orthogonal methods. The standard is reconstituted at 0.10 mg/mL in mobile phase A, and 10 µL is injected onto a 150 × 4.6 mm, 5 µm C18 column maintained at 40 °C; detection is at 215 nm with a flow rate of 1.0 mL/min. The downstream reference-material production process includes preparative purification, lyophilization in 1 mL amber vials under dry nitrogen, Karl Fischer titration for water content, headspace gas chromatography for residual solvents, ion chromatography for trifluoroacetate counterion, and amino acid analysis following Ph. Eur. 2.2.56. Compliance is governed by ISO 17034:2016 for reference material producers, ISO/IEC 17025:2017 for calibration and testing laboratories, ICH Q2(R2) for method validation, and USP <1225> for validation of compendial procedures. Terminal product types include certified α-MSH reference standard vials, system suitability test kits, and method transfer standards for peptide purity methods. A storage boundary is immediately relevant: the lyophilized cake must be equilibrated to ambient temperature inside a desiccator before opening, and reconstituted standard should be used within 72 h to avoid oxidative and hydrolytic artefacts that shift the main peak and decrease system suitability resolution.